Table 1

Characteristics of study population based on their initial exposure in the UK

TamoxifenAITotal
N4716 (100)5289 (100)10 005 (100)
Age (years)
54–59911 (19.3)716 (13.5)1627 (16.3)
60–691850 (39.2)1972 (37.3)3822 (38.2)
70+1955 (41.5)2601 (49.2)4556 (45.5)
Median (IQR)68 (62–76)70 (63–79)69 (62–78)
Year of breast cancer
2002–20052267 (48.1)670 (12.7)2937 (29.4)
2006–20091523 (32.3)1846 (34.9)3369 (33.7)
2010–2013823 (17.5)2248 (42.5)3071 (30.7)
2014–2015103 (2.2)525 (9.9)628 (6.3)
BMI (kg/m2)
<1859 (1.3)63 (1.2)122 (1.2)
18–241693 (35.9)1619 (30.6)3312 (33.1)
25–291549 (32.8)1801 (34.1)3350 (33.5)
30–34800 (17)979 (18.5)1779 (17.8)
≥35345 (7.3)548 (10.4)893 (8.9)
Missing270 (5.7)279 (5.3)549 (5.5)
Median (IQR)26 (23–30)27 (24–31)27 (24–31)
Smoking status
Never smoker2423 (51.4)2517 (47.6)4940 (49.4)
Current smoker503 (10.7)482 (9.1)985 (9.8)
Ex-smoker1761 (37.3)2268 (42.9)4029 (40.3)
Missing29 (.6)22 (.4)51 (.5)
Alcohol use
Non-drinker618 (13.1)613 (11.6)1231 (12.3)
Current3320 (70.4)3628 (68.6)6948 (69.4)
Ex-drinker480 (10.2)715 (13.5)1195 (11.9)
Missing298 (6.3)333 (6.3)631 (6.3)
Systolic BP
Low/ideal530 (11.2)599 (11.3)1129 (11.3)
Prehigh1862 (39.5)2327 (44)4189 (41.9)
High2314 (49.1)2355 (44.5)4669 (46.7)
Missing10 (.2)8 (.2)18 (.2)
Diastolic BP
Low/ideal2130 (45.2)2650 (50.1)4780 (47.8)
Prehigh1988 (42.2)2058 (38.9)4046 (40.4)
High588 (12.5)573 (10.8)1161 (11.6)
Missing10 (.2)8 (.2)18 (.2)
Index of Multiple deprivation category
1870 (18.4)962 (18.2)1832 (18.3)
2943 (20)1214 (23)2157 (21.6)
3925 (19.6)1054 (19.9)1979 (19.8)
41052 (22.3)936 (17.7)1988 (19.9)
5926 (19.6)1122 (21.2)2048 (20.5)
Missing0 (0)1 (0)1 (0)
CVD-related treatment before index
Statins1100 (23.3)1903 (36)3003 (30)
ACEi1195 (25.3)1823 (34.5)3018 (30.2)
CCB1195 (25.3)1764 (33.4)2959 (29.6)
ARB493 (10.5)795 (15)1288 (12.9)
Antiplatelets1132 (24)1639 (31)2771 (27.7)
Comorbidities before index
RA138 (2.9)137 (2.6)275 (2.7)
Diabetes462 (9.8)728 (13.8)1190 (11.9)
CKD867 (18.4)1090 (20.6)1957 (19.6)
CVD before index
Non-venous CVD1031 (21.9)1636 (30.9)2667 (26.7)
VTE before index144 (3.1)324 (6.1)468 (4.7)
  • ACEi, Angiotensin-converting-enzyme inhibitors; AI, aromatase inhibitor; ARB, angiotensin II receptor blocker; BP, blood pressure; CCB, calcium channel blocker; CKD, Chronic kidney disease; CVD, cardiovascular disease; RA, Rhematoid arthritis; VTE, venous thromboembolism.